Conference Proceedings

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S Tam, Tanya Siddiqi, John N Allan, Thomas J Kipps, Ian W Flinn, Bryone J Kuss, Stephen Opat, Paul M Barr, Alessandra Tedeschi, Ryan Jacobs, Xavier C Badoux, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Hamed Salem, Kristin Russell, Karl Eckert, Cathy Zhou, Joi Ninomoto, Danelle F James, William G Wierda

Blood | AMER SOC HEMATOLOGY | Published : 2019

Abstract

DISCLOSURES: Tam: Novartis: Honoraria; Pharmacyclics LLC, an AbbVie company: Honoraria; AbbVie: Honoraria, Research Funding; BeiGene: Honoraria; Janssen: Honoraria, Research Funding; Roche: Honoraria. Siddiqi:Astra Zeneca: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speakers Bureau; Kite: Research Funding; TG Therapeutics: Research Funding; Celgene: Research Funding; BeiGene: Research Funding; Seattle Genetics: Speakers Bureau; Janssen: Speakers Bureau; Pharmacyclics LLC, an AbbVie company: Consultancy, Research Funding, Speakers Bureau; Juno: Consultancy, Research Funding. Allan:Bayer: Consultancy; Verastem Oncology, Inc.: Consultancy, Membership on an entity's B..

View full abstract